Enzymotec (ENZY) Tops Q3 EPS by 1c; Guides FY15 EPS Above Consensus

Enzymotec (NASDAQ: ENZY) reported Q3 EPS of $0.08, $0.01 better than the analyst estimate of $0.07. Revenue for the quarter came in at $12.4 million versus the consensus estimate of $14.21 million.

Third quarter adjusted EBITDA increased 55.3% to $2.7 million*, compared to the third quarter of 2014.

Enzymotec sees FY2015 EPS of $0.36-$0.40, versus the consensus of $0.30. Enzymotec sees FY2015 revenue of $50-52 million, versus the consensus of $54.6 million.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c